Drug development for start-ups and emerging pharma (Part 1 of 2)

Sponsored by: Recipharm

Focused on:

  • Drug Development
  • Drug Substance
  • Pharmaceutical

Date: 17 February


Time: 3PM London/10AM New York

From drug candidate to proof of concept (POC)

The drug development for start-ups and emerging pharma webinar is the first of a two-part series covering development from drug candidate to launch. This first webinar will focus on the steps from drug candidate to proof of concept (POC).

The second webinar, which will take place March 24, will cover a POC to launch.

A drug development project is performed over several years and involves many different experts. For a small organisation, it is vital to choose the right partners, plan carefully and ensure effective communication to reduce risks. During this webinar, Recipharm’s experts will discuss the pharmaceutical development process from idea to POC for both drug substance and drug product development and the key considerations that need attention throughout the process.

The speakers will also cover the importance of having the end product in mind from the outset of each project and how identifying where it is you’re heading can help you to navigate the complex regulatory approval process and market launch successfully.

You can register for part one of the series here.

Presented by

Anders Högdin, Ph.D.,

Senior Business Development Director Development Services, Drug Substance

Anders Högdin is Senior Business Development Director in Recipharm’s drug substance team. Anders has a MSc in chemistry and a PhD in organic chemistry from Uppsala University and has more than 20 years' experience from the CDMO industry in roles covering a range from medicinal chemistry to process development and manufacturing of drug substance for clinical trials and commercial scale.

Mikael Bisrat, PhD (Pharm), eMBA,

Senior Business Development Director, Development Services, Drug Product

Mikael Bisrat is Senior Business Development Director in Recipharm’s drug product team with a focus on the Nordic market. Mikael, who has a Ph.D. in Pharmaceutics from Uppsala University and an EMBA from Stockholm School of Economics, has a wealth of experience in the pharmaceutical industry. He has extensive knowledge about late-stage discovery, formulation development and the production of clinical trial materials.

Gabriella Yousef,

Formulation scientist, pharmaceutical development

Gabriella Yousef is a formulation scientist at Recipharm. She holds a master’s degree in pharmacy from Uppsala University. She has experience from several CDMO companies. During her time in Recipharm she has contributed with the formulation development of several different drug products including medical devices. She also has experience in GMP from production of clinical trial material.

Aaron Small,

Vice President- Global Development Sales

Aaron Small is Vice President Global Development Sales at Recipharm. He holds a BSBA degree in Marketing and a MBA and has been a part of Recipharm since 2011. During his time in Recipharm he has contributed to business development activities for both development and manufacturing services. In addition Aaron has been a part of brand development and deployment for the North American market.

Key Learning Objectives

  • Get a clear view of the important steps of drug development until proof of concept
  • How to reduce risks in the development process
  • Understand the timeline and critical steps
  • Importance of having the end product in mind from the start


  • Analytical services - Manager/Director/Head of/VP
  • CMC - Manager/Director/Head of/VP
  • Development - Manager/Director/Head of/VP
  • Formulation development - Manager/Director/Head of/VP
  • Pharmaceutical development - Manager/Director/Head of/VP
  • Chemistry/Medicinal Chemistry - Manager/Director/Head of/VP
  • CMC - Manager/Director/Head of/VP
  • Founder and CEO
  • Procurement - Manager/Director/Head of/VP
  • CSO
  • COO